Evidence map›Paper›PMID 39803445›Full record

ArticlebioRxiv : the preprint server for biology2025

Cross-reactive sarbecovirus antibodies induced by mosaic RBD-nanoparticles.

Chengcheng Fan, Jennifer R Keeffe, Kathryn E Malecek, Alexander A Cohen, Anthony P West, Viren A Baharani, Annie V Rorick, Han Gao, Priyanthi N P Gnanapragasam, Semi Rho and 5 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Chengcheng FanDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.ORCID 0000-0003-4213-5758
Jennifer R KeeffeDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.ORCID 0000-0002-5317-6398
Kathryn E MalecekDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Alexander A CohenDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.ORCID 0000-0002-2818-656X
Anthony P WestDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Viren A BaharaniLaboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.ORCID 0009-0009-2011-9547
Annie V RorickDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.ORCID 0009-0003-1801-6940
Han GaoDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Priyanthi N P GnanapragasamDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Semi RhoDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Jaasiel AlvarezDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Luisa N SegoviaDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Theodora HatziioannouLaboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.ORCID 0000-0002-7889-0766
Paul D BieniaszLaboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.ORCID 0000-0002-2368-3719
Pamela J BjorkmanDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.ORCID 0000-0002-2277-3990

Funding

A Synchrotron Radiation Structural Biology ResourcesP30GM133894 · NIGMS · STANFORD UNIVERSITY · PI Clyde Smith · 2020 to 2026
$43.3M
The longevity and nature of the anti-SARS-CoV-2 cellular and humoral immune responsesP01AI165075 · NIAID · ROCKEFELLER UNIVERSITY · PI BIENIASZ, PAUL D., BJORKMAN, PAMELA J · 2022 to 2023
$10.7M
Gates Foundation INV-034638NIAID NIH HHS P01 AI165075NIGMS NIH HHS P30 GM133894Wellcome Trust
6 · The paper itself

Abstract

Broad immune responses are needed to mitigate viral evolution and escape. To induce antibodies against conserved receptor-binding domain (RBD) regions of SARS-like betacoronavirus (sarbecovirus) spike proteins that recognize SARS-CoV-2 variants of concern and zoonotic sarbecoviruses, we developed mosaic-8b RBD-nanoparticles presenting eight sarbecovirus RBDs arranged randomly on a 60-mer nanoparticle. Mosaic-8b immunizations protected animals from challenges from viruses whose RBDs were matched or mismatched to those on nanoparticles. Here, we describe neutralizing mAbs isolated from mosaic-8b-immunized rabbits, some on par with Pemgarda, the only currently FDA-approved therapeutic mAb. Deep mutational scanning,

Indexed as

Biological Sciencescryo-EMImmunology and Inflammationmosaic nanoparticlesarbecovirusvaccine development

Identifiers

PMID39803445
PMCPMC11722225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.